GlucoBeam®

Diabetes care: glucobeam concept drawing

Concept drawing

Glucobeam

RSP Systems is developing a device for non-invasive glucose monitoring. GlucoBeam® will entail several advantages for the individual with diabetes as well as for society at large:

  • Pain-free glucose testing with an easy-to-use device
  • Improved compliance with recommended glucose monitoring schemes (4-8 tests per day) thanks to the absence of pain and inconvenience
  • High frequency of testing made possible (no pain, no cost of test strip), leading to better glucose management
  • Fewer acute and long-term complications due to better glucose management, resulting in better quality of life and improved health economics
  • Wireless integration with a smartphone/tablet app for storing and analyzing the glucose data.
  • Integration to cloud based Internet Blood Glucose Monitoring services will also be supported, allowing patients to share their glucose data with their physician for the purpose of optimizing their treatment and minimizing the risk of complications.

Diabetes and Glucose Monitoring

Diabetes mellitus is one of the largest health challenges currently faced by modern society, reaching pandemic proportions. Today, there are 382 million people living with diabetes, a number expected to reach 592 million by 2035. A further 316 million with impaired glucose tolerance are at high risk from the disease – an alarming number that is set to reach 471 million by 2035.

In 2013, diabetes caused 5.1 million deaths, which means that every six seconds a person dies from diabetes. Moreover, it represents a cost of USD 548 billion in healthcare spending worldwide.

Self-Monitoring of Blood Glucose (SMBG) is a key element of diabetes treatment, in particular for diabetes patients taking insulin (which comprises all patients with type-1 diabetes and ~30% of patients with type-2 diabetes) The global market for glucose testing solutions exceeds USD 10 billion annually.

Self-Monitoring of Blood Glucose (SMBG) is today an invasive test, requiring the patient to prick his/her finger with a lancet to extract a blood droplet onto a disposable strip for electrochemical analysis of the glucose concentration.

The disadvantages of the incumbent SMBG technology are well-known and represent a huge challenge within diabetics’ care:

  • Discomfort and pain – leading to lower quality of life and poor compliance
  • High testing costs – increasing with the frequency of testing
  • Therapeutic decisions being made based on single glucose measurements rather than trends – because pain and cost limit the number of daily tests
  • High costs of complications – caused by poor compliance (too few tests being made)

By offering a pain-free, easy-to use non-invasive glucose monitoring solution, RSP’s GlucoBeam® has the potential to increase quality of life for diabetic patients worldwide, while reducing the overall costs of diabetic care.